Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Analysts at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $57.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 54.39% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the company. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

SUPN opened at $36.92 on Monday. The stock’s 50 day moving average price is $36.16 and its 200 day moving average price is $32.97. The stock has a market cap of $2.04 billion, a P/E ratio of 34.50 and a beta of 0.90. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same period last year, the company earned ($0.29) earnings per share. Equities analysts anticipate that Supernus Pharmaceuticals will post 2.37 EPS for the current year.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares in the company, valued at $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This represents a 11.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 154,213 shares of company stock valued at $5,660,180 over the last three months. Company insiders own 9.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in Supernus Pharmaceuticals by 0.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 425,387 shares of the specialty pharmaceutical company’s stock valued at $11,379,000 after acquiring an additional 2,427 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in Supernus Pharmaceuticals by 3.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock valued at $273,000 after buying an additional 350 shares during the period. Rhumbline Advisers increased its stake in Supernus Pharmaceuticals by 3.3% in the 2nd quarter. Rhumbline Advisers now owns 180,274 shares of the specialty pharmaceutical company’s stock valued at $4,822,000 after buying an additional 5,813 shares during the period. Victory Capital Management Inc. lifted its position in Supernus Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 735,038 shares of the specialty pharmaceutical company’s stock worth $19,662,000 after buying an additional 87,200 shares in the last quarter. Finally, Candriam S.C.A. acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at $3,795,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.